Recently, applying new strategies which could merge the strong cell killing ability of potentcytotoxic agents with target speciï city have been used and they have shown potentiallyaccurate models in cancer treatment. Antibody drug conjugates (ADCs) main goal is todeliver of highly potent cytotoxic anti-cancer drugs selectively to a tumor-specific antigen inorder to take advantage of the speciï city of monoclonal antibodies (mAbs) and bypassingthe common morbidity of conventional chemotherapy. To wit, ADCs combine the cytotoxicpotential of special chemotherapeutic drugs with the specificity of mAbs. After several yearsof unfulfilled attempt in the field of ADCs, researchers find out how these segments need tobe connected to generate a successful therapeutic agent recently. In brief, the success ofADCs is related on four parameters: target antigen, antibody, linker, and payload. In parallelto naked monoclonal antibodies, targeting a suitable antigen for ADCs is a key factor thataffects the potent toxicity profile, therapeutic window and efficacy of ADCs. Progresses overthe past two decades and antibody engineering technology have led to a new version ofADCs in comparison to conventional methods. Hence, current methods produceheterogeneous mixtures that may contain 0-8 drug species per antibody molecule. So, manystudies indicated that after speciï city of each mAbs, linkers play critical roles in thiscombination. And site-specific conjugation has been recently shown to removeheterogeneity, promote conjugate stability, and increase the therapeutic window. Inconclusion we want to focus on the concepts underlying the choice of the mAbs and linkersand discuss about how we could improve antibodies efï cacy and their sustainability. Totally,we also summarize differences between these methods and highlight critical considerationswhen constructing next-generation ADC therapeutics as well as. In addition, we will discussabout current ADCs and their targets, and then look to the future of ADCs.